Communiqués Jade Biosciences, Inc.

Actions

JBIO

US0080642061

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:17:54 15/09/2026			Varia. 5j.	Varia. 1 janv.
17,18 ^USD	-5,53 %		-11,11 %	+12,05 %

09/09	Transcript : Jade Biosciences, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 09:20 AM
04/09	Les données de phase 1 de Climb Bio pour son traitement de la néphropathie à IgA jugées 'positives' par Wedbush	MT

Communiqués

01/09	Jade Biosciences to Participate in Upcoming Conferences	AQ
10/08	Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
26/06	Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors	AQ
05/06	Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
04/06	Jade Biosciences Announces Pricing of Public Offering of Common Stock	AQ
03/06	Jade Biosciences Announces Proposed Underwritten Public Offering	AQ
01/06	Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy	AQ
29/05	Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy	AQ
26/05	Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody	AQ
26/05	Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy	AQ
08/05	Jade Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
23/04	Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
22/04	Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer	AQ
06/03	Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
11/02	Jade Biosciences to Participate in Upcoming Conferences	AQ
05/01	Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference	AQ
15/12	Jade Biosciences Announces $45 Million Private Placement	AQ
13/11	Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
08/11	Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025	AQ
03/11	Jade Biosciences to Participate in Upcoming Conferences	AQ
17/10/25	Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025	AQ
07/10/25	Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases	AQ
07/10/25	Jade Biosciences Announces $135 Million Private Placement	AQ
02/09/25	Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy	AQ